Suggested remit - To appraise the clinical and cost effectiveness of avelumab within its marketing authorisation for platinum-resistant and platinum-refractory ovarian cancer.
Following an update from the company this appraisal is now suspended.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 January 2019 | Suspended. Following an update from the company this appraisal is now suspended. |
| 15 November 2018 - 13 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 1497 |
| 22 November 2018 | Note added to the project documents |
| 24 April 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual